Spinal Cord InjuriesCAVERSTIMNCT06347575
Safety and Tolerability of a Novel Implantable Neurostimulator for Ameliorate Erectile Function on Spinal Cord Injured Patients
A study testing Implantation of the caverStim device in people with Spinal Cord Injuries and Erectile Dysfunction, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
The main objective of the study is to assess the safety and tolerability of cavernous nerve electrical stimulation in patients with spinal cord injured (SCI) by assessing and measuring complications. Read more about this study
- Who is it for?
- Ages 18 to 45 years, men only
- Conditions the study is for
- Spinal Cord Injuries, Erectile Dysfunction
- What is being tested?
- Implantation of the caverStim device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteFrance
- Study dates
- May 2024to Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- Subjects have to fulfill all of the following inclusion criteria before being included in the run-in phase:
- Written informed consent obtained from the subject;
- Men between the age of 18 to 45 years old with supra sacral spinal cord injury and below T6 as the upper limit;
- Men with stable spinal cord injury, which occurred at least 6 months prior to study enrolment;
- Men with documented neurogenic overactive detrusor activity according to urodynamic testing in their files;
- Have a monogamous relationship with a female sexual partner (vaginal penetration required for several of the primary efficacy variables) for at least 6 months prior to screening
Show all 13Show fewer
- Men with an insufficient response to PDE5-Is and interested in treating erectile dysfunction;
- Ability to understand and follow study-related instructions.
- Subjects have to fulfill all of the following inclusion criteria before being included in the implantation phase:
- At least 4 sexual intercourse attempts during the 4-week run-in phase with use of 100 mg sildenafil approximately 1 hour before attempting intercourse
- IIEF-EF score < 17 at the end of the run-in phase;
- At least 50% of attempts at sexual intercourse during the run-in phase had been unsuccessful i.e. the following question in the SEP Diary had to be answered with "No":
- "Did your erection last long enough for you to have successful intercourse?" (SEP3: success in maintenance of erection).
Who cannot join
- All exclusion criteria will be assessed before the 4-week run-in phase.
- The presence of any one of the following exclusion criteria will lead to exclusion of the subject:
- Patients with spinal cord lesion at T6 or above;
- Patients with known allergies to any of the device material (Platinum/iridium, silicone, pellethane, titanium, polysulfone, polyurethane);
- Patients contraindicated for surgery under general anesthesia;
- History of priapism or Lapeyronie's disease;
Show all 18Show fewer
- Patients having met the criteria for unstable angina within 6 months prior to Visit 1, history of myocardial infarction or coronary artery bypass graft surgery within 90 days prior to Visit 1, or percutaneous coronary intervention (eg, angioplasty or stent placement) within 90 days prior to Visit 1.
- Any supraventricular arrhythmia with an uncontrolled ventricular response (mean heart rate >100 bpm) at rest despite medical therapy, or any history of spontaneous or induced sustained ventricular tachycardia (heart rate >100 bpm for >=30 sec) despite medical therapy;
- A history of sudden cardiac death (arrest) despite medical therapy.
- Any evidence of congestive heart failure within 6 months prior to Visit 1.
- History of previous pelvic surgery or irradiation therapy;
- Prior surgery for an implantable penile prosthesis;
- Inability to understand and to follow instructions on device use;
- Patients with diabetes mellitus
- Patients not interested in sexual activity;
- Patients currently participating in another clinical investigation;
- Patient has participated in any drug or device trial in the last 4 weeks or plans to participate in any other drug or device study in the next 24 months;
- Any other characteristics that, per the investigator's judgment, may increase the patients risk or impair the study conduct and data collection; such as depression or abnormal behavior for example.
Trial locations and contacts
1 site in 1 country.
France1 site
Department of neurology-urology-andrology, Raymond Poincaré hospital - APHP
Garches, 92380
About this study
Official title: Safety and Tolerability of a Novel Implantable Neurostimulator for Ameliorate Erectile Function: a Pilot Study in Spinal Cord Injured Patients
The main objective of the study is to assess the safety and tolerability of cavernous nerve electrical stimulation in patients with spinal cord injured (SCI) by assessing and measuring complications.
As the secondary objectives, despite the limited cohort size, this long-term study aims to obtain preliminary data on efficacy of cavernous nerve stimulation to improve erectile function for sexual intercourse, as well as to assess patient's satisfaction using:
Read more
- Objective assessment of the erectile response upon CaverSTIM activation with the RigiScan device.
- Subjective assessment of the erectile function with validated questionnaires:
- A 6-item self-report instrument assessing male erectile function (Erectile Function domain of the International Index of Erectile Function, IIEF-EF);
- A log-diary five item questionnaire completed after each sexual attempt (Sexual Encounter Profile, SEP);
- A self-reporting measure that scores erection hardness on a 4-point scale (Erection Hardness Score, EHS);
- The Global Assessment Question (GAQ).
In addition, the study aims to refine the method of implantation (step-by-step delineation of all technical approaches for device implantation, including duration of surgical procedure, blood loss, methods to access the periprostatic region, tissue dissection, device placement and fixation) prior to planning for larger scale clinical investigation.
Read the detailed description
Depending on the location and whether the spinal cord lesion is complete or not, oral medications (phosphodiesterase type 5 (PDE5-Is) inhibitors, eg Viagra®) may be more or less effective in improving erectile function. When these drugs are not sufficiently effective, the second-line pharmacological treatment for SCI patients consists of intracavernous injections. Treatment by intracavernous injections is responsible for additional constraints. Indeed, a titration must be carried out in a doctor's office (important to minimize the risk of priapism). Specific learning of the injection technique must also be implemented for the patient and/or his partner, the identification of the injection site (laterally in the cavernous bodies at an angle of 90° with respect to the long axis of penis, avoiding the urethra and subcutaneous veins) and aseptic handling. The use of intracavernous injections is often abandoned by patients due to a high level of discomfort, complicated self-injection or lack of spontaneity during sexual intercourse. In patients with SCI, intracavernous injections of prostaglandin E1 fail to induce a sufficiently rigid erection in 20% of them. Vacuum device is another option. Nevertheless it may be perceived as cumbersome and lacking of spontaneity. In case of failure or lack of acceptance of intracavernous injections and vacuumdevice, the penile implant, which consists of a pair of malleable or inflatable cylinders surgically implanted in the cavernous bodies previously destroyed surgically, is the third-line treatment. However, penile implants have an increased risk of infection in patients with SCI, according to two large studies. Thus, effective, acceptable and safe treatment alternatives are sought by patients with SCI who are insufficiently responsive to oral treatments.
The concept of electro-neurostimulation therapy to activate the cavernous nerves for erectile dysfunction was introduced two decades ago. Despite its recognized potential and the first promising studies confirming the feasibility of peri-prostatic cavernous nerve stimulation, this technology has not yet been developed. The difficulty lies in the complex anatomy of the human cavernous nerve. Indeed, it is difficult to identify the optimal site for stimulation because the human cavernous nerve is not visible on a macroscopic scale and extends from the pelvic plexus to the penis through a peri-vesical and peri-prostatic neuroplexus. whose anatomy is complex. In addition, the course of the cavernous nerve is subject to strong interindividual variability. In addition to these intrinsic anatomical problems, other difficulties are encountered during the surgical intervention, such as the presence of overlying tissues, connective tissue and potential bleeding obstructing the operative field, thus making the optimal placement of the implants complex.. The main difficulty in applying neurostimulation to the treatment of erectile dysfunction is therefore to identify the stimulation site to place the stimulation electrodes in optimal contact with the cavernous nerve.
A practical solution was invented by a patch with twelve electrodes. This solution was designed to promote extensive contact with the cavernous nerve. The concept was developed to allow implantation of the electrodes regardless of the visibility of the cavernous nerve bundles. This concept makes it possible to globally cover the anatomical region of interest where the cavernous nerve is supposed to be located, while taking into account the great heterogeneity of its course. This approach then guarantees optimal contact of at least a few electrodes with the cavernous nerve and thus offers optimal stimulation conditions.
The multi-electrode patches will be implanted during a robotic laparoscopic surgical procedure. A stimulation test will be performed during the operation to ensure that the patient responds to stimulation (erectile response) before the device is permanently implanted. Following the recovery of the patient, the selection of the stimulation parameters will be carried out on an outpatient basis in order to identify the electrode(s) which give(s) the best erectile response. The electrodes in contact with the cavernous nerve bundles (causing the maximum erectile response) will then be selected and recorded for stimulation/therapy.
- Conditions
- Spinal Cord Injuries, Erectile Dysfunction
- Being tested
- Implantation of the caverStim device
- Keywords
- spinal cord injuried, penile erection, electrical stimulation, implantable, pilot study, cavernous nerve
- Medical subject headings
- Spinal Cord Injuries, Erectile Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Implantation of the caverStim deviceDevice
Implantation of caverStim in SCI patients.
| Study group | Role | What they receive |
|---|---|---|
| Implantation of the caverStim device | Experimental | Implantation of caverStim in SCI patients Receives: Device: Implantation of the caverStim device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety evaluation
The safety of the CaverSTIM device will be assessed by systematically reporting device failures, adverse events including serious adverse events, while monitoring the frequency, severity and incidence of these events.
Measured: at 6 months
Pain assessement
Pain will be assessed during the days following the implant surgery as well as during activation of the device, by asking the subject to rate their pain from 0 to 10 using a visual analogue scale (VAS).
Measured: at 6 months
Complications related to implantation surgery
Complications related to implantation surgery should be evaluated and classified according to the Clavien-Dindo classification.
Measured: at 6 months
Secondary outcomes (4)
Evaluation of IIEF-EF
Subjective evaluation of penile erection and sexual satisfaction of the subject by means of validated questionnaires:
IIEF-EF (Erectile Function domain score from the International Index of Erectile Function)
Measured: at 6 months
Evaluation of EHS
Subjective evaluation of penile erection and sexual satisfaction of the subject by means of validated questionnaires:
EHS (Erection Hardness Score)
Measured: at 6 months
Evaluation of SEP
Subjective evaluation of penile erection and sexual satisfaction of the subject by means of validated questionnaires:
SEP (Sexual Encounter Profile)
Measured: at 6 months
Evaluation of GAQ
Subjective evaluation of penile erection and sexual satisfaction of the subject by means of validated questionnaires:
GAQ (Global Assessment Question).
Measured: at 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2024
- Study startMay 2024 (estimated)
- Primary completionNov 2025 (estimated)
- Study completionNov 2025 (estimated)
Why it stopped: The company that supplies the Medical Device has withdrawn.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Spinal Cord InjuriesStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Collaborators
- Comphya SA
- Responsible party
- Sponsor
- Investigators
- François Giuliano, MD, PhD, Principal investigator, Department of neurology-urology-andrology, Raymond Poincaré hospital - APHPEmmanuel CHARTIER-KASTLER, MD, PhD, Study director, Department of Urology, La Pitié-Salpétrière hospital - APHPAnne Charlotte DENORMANDIE, MD, Study director, Department of Urology, La Pitié-Salpétrière hospital - APHP
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06347575
- Sponsor's protocol ID
- APHP230522
- Acronym
- CAVERSTIM
- Status last verified
- Jun 2025
- First submitted
- 2 Oct 2023
- Last updated
- 15 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Tolerability of a Novel Implantable Neurostimulator for Ameliorate Erectile Function: a Pilot Study in Spinal Cord Injured Patients
- ClinicalTrials.gov ID
- NCT06347575
- Acronym / sponsor ID
- CAVERSTIM / APHP230522
- Conditions
- Spinal Cord Injuries, Erectile Dysfunction
- Keywords
- spinal cord injuried, penile erection, electrical stimulation, implantable, pilot study, cavernous nerve
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: The company that supplies the Medical Device has withdrawn.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Collaborators
- Comphya SA
- Study start
- May 2024 (estimated)
- Primary completion
- Nov 2025 (estimated)
- Study completion
- Nov 2025 (estimated)
- First posted
- 4 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of the study is to assess the safety and tolerability of cavernous nerve electrical stimulation in patients with spinal cord injured (SCI) by assessing and measuring complications.
As the secondary objectives, despite the limited cohort size, this long-term study aims to obtain preliminary data on efficacy of cavernous nerve stimulation to improve erectile function for sexual intercourse, as well as to assess patient's satisfaction using:
- Objective assessment of the erectile response upon CaverSTIM activation with the RigiScan device.
- Subjective assessment of the erectile function with validated questionnaires:
- A 6-item self-report instrument assessing male erectile function (Erectile Function domain of the International Index of Erectile Function, IIEF-EF);
- A log-diary five item questionnaire completed after each sexual attempt (Sexual Encounter Profile, SEP);
- A self-reporting measure that scores erection hardness on a 4-point scale (Erection Hardness Score, EHS);
- The Global Assessment Question (GAQ).
In addition, the study aims to refine the method of implantation (step-by-step delineation of all technical approaches for device implantation, including duration of surgical procedure, blood loss, methods to access the periprostatic region, tissue dissection, device placement and fixation) prior to planning for larger scale clinical investigation.
Detailed description
Depending on the location and whether the spinal cord lesion is complete or not, oral medications (phosphodiesterase type 5 (PDE5-Is) inhibitors, eg Viagra®) may be more or less effective in improving erectile function. When these drugs are not sufficiently effective, the second-line pharmacological treatment for SCI patients consists of intracavernous injections. Treatment by intracavernous injections is responsible for additional constraints. Indeed, a titration must be carried out in a doctor's office (important to minimize the risk of priapism). Specific learning of the injection technique must also be implemented for the patient and/or his partner, the identification of the injection site (laterally in the cavernous bodies at an angle of 90° with respect to the long axis of penis, avoiding the urethra and subcutaneous veins) and aseptic handling. The use of intracavernous injections is often abandoned by patients due to a high level of discomfort, complicated self-injection or lack of spontaneity during sexual intercourse. In patients with SCI, intracavernous injections of prostaglandin E1 fail to induce a sufficiently rigid erection in 20% of them. Vacuum device is another option. Nevertheless it may be perceived as cumbersome and lacking of spontaneity. In case of failure or lack of acceptance of intracavernous injections and vacuumdevice, the penile implant, which consists of a pair of malleable or inflatable cylinders surgically implanted in the cavernous bodies previously destroyed surgically, is the third-line treatment. However, penile implants have an increased risk of infection in patients with SCI, according to two large studies. Thus, effective, acceptable and safe treatment alternatives are sought by patients with SCI who are insufficiently responsive to oral treatments.
The concept of electro-neurostimulation therapy to activate the cavernous nerves for erectile dysfunction was introduced two decades ago. Despite its recognized potential and the first promising studies confirming the feasibility of peri-prostatic cavernous nerve stimulation, this technology has not yet been developed. The difficulty lies in the complex anatomy of the human cavernous nerve. Indeed, it is difficult to identify the optimal site for stimulation because the human cavernous nerve is not visible on a macroscopic scale and extends from the pelvic plexus to the penis through a peri-vesical and peri-prostatic neuroplexus. whose anatomy is complex. In addition, the course of the cavernous nerve is subject to strong interindividual variability. In addition to these intrinsic anatomical problems, other difficulties are encountered during the surgical intervention, such as the presence of overlying tissues, connective tissue and potential bleeding obstructing the operative field, thus making the optimal placement of the implants complex.. The main difficulty in applying neurostimulation to the treatment of erectile dysfunction is therefore to identify the stimulation site to place the stimulation electrodes in optimal contact with the cavernous nerve.
A practical solution was invented by a patch with twelve electrodes. This solution was designed to promote extensive contact with the cavernous nerve. The concept was developed to allow implantation of the electrodes regardless of the visibility of the cavernous nerve bundles. This concept makes it possible to globally cover the anatomical region of interest where the cavernous nerve is supposed to be located, while taking into account the great heterogeneity of its course. This approach then guarantees optimal contact of at least a few electrodes with the cavernous nerve and thus offers optimal stimulation conditions.
The multi-electrode patches will be implanted during a robotic laparoscopic surgical procedure. A stimulation test will be performed during the operation to ensure that the patient responds to stimulation (erectile response) before the device is permanently implanted. Following the recovery of the patient, the selection of the stimulation parameters will be carried out on an outpatient basis in order to identify the electrode(s) which give(s) the best erectile response. The electrodes in contact with the cavernous nerve bundles (causing the maximum erectile response) will then be selected and recorded for stimulation/therapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Implantation of the caverStim device | Experimental | Device: Implantation of the caverStim deviceImplantation of caverStim in SCI patients |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (13 listed)
- Subjects have to fulfill all of the following inclusion criteria before being included in the run-in phase:
- Written informed consent obtained from the subject;
- Men between the age of 18 to 45 years old with supra sacral spinal cord injury and below T6 as the upper limit;
- Men with stable spinal cord injury, which occurred at least 6 months prior to study enrolment;
- Men with documented neurogenic overactive detrusor activity according to urodynamic testing in their files;
Key exclusion criteria (18 listed)
- All exclusion criteria will be assessed before the 4-week run-in phase.
- The presence of any one of the following exclusion criteria will lead to exclusion of the subject:
- Patients with spinal cord lesion at T6 or above;
- Patients with known allergies to any of the device material (Platinum/iridium, silicone, pellethane, titanium, polysulfone, polyurethane);
- Patients contraindicated for surgery under general anesthesia;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Implantation of the caverStim deviceImplantation of caverStim in SCI patients. | Device | Implantation of the caverStim device |
Primary outcome
Safety evaluation
Time frame: at 6 months
The safety of the CaverSTIM device will be assessed by systematically reporting device failures, adverse events including serious adverse events, while monitoring the frequency, severity and incidence of these events.
Pain assessement
Time frame: at 6 months
Pain will be assessed during the days following the implant surgery as well as during activation of the device, by asking the subject to rate their pain from 0 to 10 using a visual analogue scale (VAS).
Complications related to implantation surgery
Time frame: at 6 months
Complications related to implantation surgery should be evaluated and classified according to the Clavien-Dindo classification.
4 secondary outcomes
Evaluation of IIEF-EF
Time frame: at 6 months
Evaluation of EHS
Time frame: at 6 months
Evaluation of SEP
Time frame: at 6 months
Evaluation of GAQ
Time frame: at 6 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2025.
Related trials for Spinal Cord Injuries
Recruiting
MyHand-SCI: An Active Hand Orthosis for Spinal Cord Injury
Spinal Cord Injuries, Tetraplegia
Recruiting
Clinical Outcome Assessment for AT & BCI
Spinal Cord Injury, ALS (Amyotrophic Lateral Sclerosis)
Recruiting
Transcutaneous Spinal Cord Stimulation Combined With 4-Aminopyridine and Intensive Rehabilitation in SCI
Spinal Cord Injuries
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
Chronic Spinal Cord Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
François Giuliano, MD, PhD principal investigator
Department of neurology-urology-andrology, Raymond Poincaré hospital - APHP
Emmanuel CHARTIER-KASTLER, MD, PhD study director
Department of Urology, La Pitié-Salpétrière hospital - APHP
Anne Charlotte DENORMANDIE, MD study director
Department of Urology, La Pitié-Salpétrière hospital - APHP
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Implantation of the caverStim device in people with Spinal Cord Injuries and Erectile Dysfunction, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 15 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety evaluation (time frame: at 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2025.